EMOQUETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMOQUETTE (EMOQUETTE).
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
| Metabolism | EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%). |
| Half-life | Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment. |
| Protein binding | Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments. |
| Bioavailability | Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30–60 minutes; intravenous: 5–10 minutes. |
| Duration of Action | Oral: 6–8 hours; intravenous: 4–6 hours with dose-dependent effects. |
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment needed. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: use with caution; maximum dose 1 mg per day. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day. |
| Geriatric use | Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMOQUETTE (EMOQUETTE).
| Breastfeeding | EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose. |
| Teratogenic Risk | EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy. |
■ FDA Black Box Warning
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
| Serious Effects |
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (CrCl < 15 mL/min)
| Precautions | Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles. |
Loading safety data…
| Fetal Monitoring | For pregnant women inadvertently exposed: immediate fetal ultrasound for anomalies, serial growth scans every 4 weeks, and monitoring for oligohydramnios. In non-pregnant women, a pregnancy test must be performed before each cycle and monthly thereafter. Effective contraception is mandatory. |
| Fertility Effects | EMOQUETTE reversibly reduces fertility in animal models via disruption of folliculogenesis and ovulation. In women, it may cause anovulation and luteal phase defects; effects resolve within 3 months of discontinuation. |